Company: Biogen
Tags: pipeline, territory
Eight months into detailing Leqembi and the market is moving, just not as fast as anyone projected. We're finally seeing infusion centers get their workflows sorted and the amyloid PET access issues are improving in my region. Neurologists who were skeptical a year ago are now actually initiating. The ARIA monitoring burden is real and it's still the #1 objection but we've gotten better at the conversation. My honest take: if you're patient and you work the right accounts, this is going to be a big product. The reps who quit early missed the build. I'm in it for the long haul.
10 upvotes · 0 comments